NasdaqGS - Nasdaq Real Time Price USD

Immunocore Holdings plc (IMCR)

37.25

-0.77

(-2.03%)

At close: June 6 at 4:00:01 PM EDT

37.30

+0.05

+(0.13%)

After hours: June 6 at 4:05:49 PM EDT

Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 65.2% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 5 days ago

IMCR
-2.03%
Immunocore to present at the 2025 Jefferies Global Healthcare Conference

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, June 2, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the 2025 Jefferies Global Healthcare Conference. 2024 Jefferies Global Healthcare C

GlobeNewswire 5 days ago

IMCR
-2.03%
Is it a Good Idea to Invest in Immunocore Stock Right Now?

IMCR revenues surge on robust Kimmtrak sales performance. The momentum is likely to continue in 2025.

Zacks 15 days ago

IMCR
-2.03%
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

The mean of analysts' price targets for Immunocore (IMCR) points to an 114.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks 22 days ago

IMCR
-2.03%
Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics

The headline numbers for Immunocore (IMCR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks last month

IMCR
-2.03%
Immunocore reports first quarter financial results and provides a business update

Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable s

GlobeNewswire last month

IMCR
-2.03%
Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 107.5% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks last month

IMCR
-2.03%
Immunocore to present at upcoming investor conferences

Immunocore to present at upcoming investor conferences (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 April 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that management will participate in the following investor conf

GlobeNewswire 2 months ago

IMCR
-2.03%
Immunocore Holdings plc (IMCR): Among Stocks Receiving the Most Insider Love in March

We recently published a list of Insiders Are Spending Big: 15 Stocks Leading in March. In this article, we are going to take a look at where Immunocore Holdings plc (NASDAQ:IMCR) stands against other stocks that are receiving the most insider investment in March. “The economy is strong overall and has made significant progress toward […]

Insider Monkey 2 months ago

IMCR
-2.03%
Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?

Immunocore (IMCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks 2 months ago

IMCR
-2.03%
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025 IMC-M113V was well tolerated, with no dose-limiting toxicities Signals of dose-dependent reduction in active reservoir, and viral control after complete antiretroviral treatment interruption in some PLWH Enrollment in MAD portion of the trial continues with higher doses being evaluated (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 10 March 2025) I

GlobeNewswire 2 months ago

IMCR
-2.03%
The Immunocore Holdings plc (NASDAQ:IMCR) Full-Year Results Are Out And Analysts Have Published New Forecasts

As you might know, Immunocore Holdings plc ( NASDAQ:IMCR ) recently reported its annual numbers. Revenues were in line...

Simply Wall St. 3 months ago

IMCR
-2.03%
Immunocore Holdings Full Year 2024 Earnings: Misses Expectations

Immunocore Holdings ( NASDAQ:IMCR ) Full Year 2024 Results Key Financial Results Revenue: US$310.2m (up 24% from FY...

Simply Wall St. 3 months ago

IMCR
-2.03%
Immunocore Holdings PLC (IMCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Immunocore Holdings PLC (IMCR) reports a 30% annual revenue increase, driven by KIMMTRAK's robust performance and expanded clinical trials.

GuruFocus.com 3 months ago

IMCR
-2.03%
Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

KIMMTRAK (tebentafusp) Q4 net sales of $84.1 million and $310.0 million for full year 2024; continued growth expected in 2025 Executing on KIMMTRAK lifecycle management with two Phase 3 trials (TEBE-AM and ATOM) in additional melanoma indications Advancing PRAME portfolio – first patient randomized in Phase 3 PRISM-MEL-301; enrollment continues in Phase 1/2 trial of brenetafusp combinations in ovarian cancer and NSCLC; first patient dosed in Phase 1 trial of IMC-P115C (PRAME-A02-HLE) First patie

GlobeNewswire 3 months ago

IMCR
-2.03%
Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO

Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.

Pharma Voice 3 months ago

IMCR
-2.03%

LLY
Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 19 February 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced that it will report financial results for the fourth quarter and year ended December 31, 2024 on Wednesday, Februar

GlobeNewswire 3 months ago

IMCR
-2.03%
Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?

IMCR's fourth-quarter 2024 earnings are likely to have gained from higher sales of its sole marketed product, Kimmtrak.

Zacks 3 months ago

IMCR
-2.03%
Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 113.1% in Immunocore (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 4 months ago

IMCR
-2.03%

Performance Overview

Return	IMCR	MSCI WORLD (^990100-USD-STRD)
YTD	+28.32%	+5.58%
1-Year	-10.63%	+12.53%
3-Year	+7.19%	+40.65%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Immunocore Holdings plc (IMCR)

Wall Street Analysts Think Immunocore (IMCR) Could Surge 65.22%: Read This Before Placing a Bet

Immunocore to present at the 2025 Jefferies Global Healthcare Conference

Is it a Good Idea to Invest in Immunocore Stock Right Now?

Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High?

Compared to Estimates, Immunocore (IMCR) Q1 Earnings: A Look at Key Metrics

Immunocore reports first quarter financial results and provides a business update

Wall Street Analysts Think Immunocore (IMCR) Could Surge 107.45%: Read This Before Placing a Bet

Immunocore to present at upcoming investor conferences

Immunocore Holdings plc (IMCR): Among Stocks Receiving the Most Insider Love in March

Immunocore (IMCR) Moves 6.0% Higher: Will This Strength Last?

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

The Immunocore Holdings plc (NASDAQ:IMCR) Full-Year Results Are Out And Analysts Have Published New Forecasts

Immunocore Holdings Full Year 2024 Earnings: Misses Expectations

Immunocore Holdings PLC (IMCR) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ...

Immunocore reports fourth quarter and full year 2024 financial results and provides a business update

Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO

Immunocore to report fourth quarter and full year 2024 financial results and host call on February 26, 2025

Immunocore Gears Up to Report Q4 Earnings: Is a Beat in Store?

Wall Street Analysts Believe Immunocore (IMCR) Could Rally 113.13%: Here's is How to Trade

Performance Overview